Findings

What do systematic reviews say?

114 questions · 114 findings · 9 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 51 · 44.7%GRADE not reported 5 · 4.4%Very low 18 · 15.8%Low 21 · 18.4%Moderate 18 · 15.8%High 1 · 0.9%

Intervention not reported

Atropine plus bifocal spectacles vs cyclopentolate plus SVLs · children with myopia (nearsightedness)

1 finding from 1 review

Interventions to slow progression of myopia in children 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Moderate

Laser trabeculoplasty vs medication

Failure to control IOP (as defined by study investigators) · people with open‐angle glaucoma

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Laser trabeculoplasty vs trabeculectomy

Failure to stabilise optic neuropathy progression (as defined by study investigators) · people with open‐angle glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser trabeculoplasty vs trabeculectomy

Quality of life · people with open‐angle glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser trabeculoplasty vs trabeculectomy

Adverse effects:PAS formation · people with open‐angle glaucoma

It is very uncertain whether laser trabeculoplasty changes adverse effectsPAS formation compared with trabeculectomy (very low certainty).

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
RR 1.78
Studies not reported
Very low

Laser trabeculoplasty vs trabeculectomy

Adverse effects: IOP spikes · people with open‐angle glaucoma

It is very uncertain whether laser trabeculoplasty changes adverse effects: IOP spikes compared with trabeculectomy (very low certainty).

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
RR 1.78
Studies not reported
Very low

Laser trabeculoplasty vs medication

Failure to stabilise visual field progression (as defined by study investigators) · people with open‐angle glaucoma

Laser trabeculoplasty showed no clear difference in failure to stabilise visual field progression (as defined by study… compared with medication (moderate certainty).

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
RR 0.7 [0.42, 1.16]
Studies not reported
Moderate

Laser trabeculoplasty vs medication

Failure to stabilise optic neuropathy progression (as defined by study investigators) · people with open‐angle glaucoma

It is very uncertain whether laser trabeculoplasty changes failure to stabilise optic neuropathy progression (as defined by… compared with medication (very low certainty).

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
RR 0.73 [0.44, 1.2]
Studies not reported
Very low

Laser trabeculoplasty vs medication

Quality of life measures · people with open‐angle glaucoma

Laser trabeculoplasty showed no clear difference in quality of life measures compared with medication (moderate certainty).

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
MD 0.28
Studies not reported
Moderate

Laser trabeculoplasty vs medication

Adverse effects:PAS formation · people with open‐angle glaucoma

Laser trabeculoplasty may leads to higher adverse effects:PAS formation compared with medication (low certainty).

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
RR 11.74 [5.94, 23.22]
Studies not reported
Low

Laser trabeculoplasty vs medication

Adverse effects: IOP spikes · people with open‐angle glaucoma

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Laser trabeculoplasty vs medication

Costs · people with open‐angle glaucoma

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Laser trabeculoplasty vs trabeculectomy

Failure to control IOP (as defined by study investigators) · people with open‐angle glaucoma

Laser trabeculoplasty may leads to higher failure to control IOP (as defined by study investigators) compared with trabeculectomy (low certainty).

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
RR 2.12 [1.44, 3.11]
Studies not reported
Low

Laser trabeculoplasty vs trabeculectomy

Failure to stabilise visual field progression (as defined by study investigators) · people with open‐angle glaucoma

1 finding from 1 review

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Rho kinase inhibitor vs placeboa

Glaucoma progression at 12 months, measured by additional visual field defects · people with primary open‐angle glaucoma or ocular hypertension

The review found no eligible studies for this question.

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rho kinase inhibitor vs beta‐blocker

Glaucoma progression at 12 months, defined by anatomic (structural) criteriab · people with primary open‐angle glaucoma or ocular hypertension

The review found no eligible studies for this question.

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rho kinase inhibitor vs beta‐blocker

Patient‐reported outcome at the longest · people with primary open‐angle glaucoma or ocular hypertension

The review found no eligible studies for this question.

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rho kinase inhibitor vs beta‐blocker

Mean change in the number of glaucoma medications at the longest · people with primary open‐angle glaucoma or ocular hypertension

The review found no eligible studies for this question.

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rho kinase inhibitor vs beta‐blocker

Need for extra treatment · people with primary open‐angle glaucoma or ocular hypertension

The review found no eligible studies for this question.

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rho kinase inhibitor vs beta‐blocker

Number of ocular adverse events at the longest · people with primary open‐angle glaucoma or ocular hypertension

1 finding from 1 review

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1678 participants
Moderate